Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index >= 27 kg/m(2)

DSpace Repository

Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index >= 27 kg/m(2)

Author: Mathieu, Chantal; Dandona, Paresh; Birkenfeld, Andreas L.; Hansen, Troels Krarup; Iqbal, Nayyar; Xu, John; Repetto, Enrico; Scheerer, Markus Florian; Thoren, Fredrik; Phillip, Moshe
Tübinger Autor(en):
Birkenfeld, Andreas L.
Published in: Diabetes Obesity & Metabolism (2020), Bd.
Verlagsangabe: Wiley
Language: English
Full text: http://dx.doi.org/10.1111/dom.14144
ISSN: 1463-1326
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)